Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 7/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046072 | 1.00 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL11113477 | 0.94 | DPP4 (0.42) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL13784784 | 0.88 | DPP4 (0.44) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL8564777 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL8564779 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL4327210 | 0.85 | FAP (0.41) | DPP4PREPFAPF2NPSR1 | |
| SCHEMBL4330609 | 0.85 | FAP (0.41) | DPP4PREPFAPF2NPSR1 | |
| SCHEMBL29985759 | 0.85 | PREP (0.44) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29380104 | 0.85 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29874508 | 0.85 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION | 2025-01-16 | — | — | US | disclosed |
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-3281939-B1 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4059923-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-14 | — | — | US | disclosed |
| EP-3972646-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1501813-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| WO-2003091232-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | WO | disclosed |
| US-20030050242-A1 | Protein polymerization inhibitors and methods of use | TRIPEP AB (SE) | 2003-03-13 | — | — | US | disclosed |
| US-20020091086-A1 | Peptides that block viral infectivity and methods of use thereof | VAHLNE ANDERS (SE) | 2002-07-11 | — | — | US | disclosed |
| EP-1207897-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2002-05-29 | — | — | EP | disclosed |
| US-6258932-B1 | TRIPEPTIDE OF DEFINED AMINO ACID SEQUENCE AND HAVING A C-TERMINAL AMIDE; VIRICIDES; TREATMENT AND PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (BE) | 2001-07-10 | — | — | US | disclosed |
| WO-2001010457-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDES | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | DPP4 693/4885PREP 166/4885FAP 1958/4885 |
| US-20250019418-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | MB, HMBS, HCCS | DPP4 3985/4885PREP 1926/4885FAP 1691/4885 |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | DPP4 377/4885PREP 3855/4885FAP 4577/4885 |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | DPP4 1014/4885PREP 3968/4885FAP 4684/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | DPP4 380/4885PREP 10/4885FAP 1000/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | DPP4 107/4885PREP 154/4885FAP 4359/4885 |
| US-20220218834-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | HBG1, HBG2, LPO | DPP4 2437/4885PREP 522/4885FAP 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.